NOMACOPAN ( DrugBank: Nomacopan )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 162 | 類天疱瘡（後天性表皮水疱症を含む。） | 3 |
162. 類天疱瘡（後天性表皮水疱症を含む。）
臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05061771 (ClinicalTrials.gov) | May 6, 2022 | 15/9/2021 | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) | A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) | Bullous Pemphigoid | Drug: nomacopan (rVA576);Other: Placebo | AKARI Therapeutics | NULL | Withdrawn | 18 Years | 99 Years | All | 0 | Phase 3 | United States;Germany;Netherlands;Poland |
| 2 | EUCTR2020-005987-67-NL (EUCTR) | 22/04/2022 | 24/11/2021 | A study to see if 24-weeks of treatment with nomacopan works and is safe in adult patients with bullous pemphigoid who are also being treated with steroid tablets | A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy (ARREST-BP) | moderate to severe bullous pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: nomacopan Product Code: rVA576 INN or Proposed INN: NOMACOPAN Other descriptive name: rVA576 | Akari Therapeutics Plc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 3 | United States;Germany;Netherlands | ||
| 3 | EUCTR2020-005987-67-DE (EUCTR) | 22/12/2021 | 16/07/2021 | A study to see if 24-weeks of treatment with nomacopan works and is safe in adult patients with bullous pemphigoid who are also being treated with steroid tablets | A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy (ARREST-BP) | moderate to severe bullous pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: nomacopan Product Code: rVA576 INN or Proposed INN: NOMACOPAN Other descriptive name: rVA576 | Akari Therapeutics Plc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 3 | United States;Germany |